During a walk following a November rain, Geoff Geiger paused by this Gingko tree in Central Alameda. He found the scent of ...

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

There’s plenty of empty lab space around Greater Boston these days, and a lot of competition for life-science tenants. Now Ginkgo Bioworks is throwing some space in the Seaport it doesn’t need right ...

Administration of Ginkgo biloba extract did not significantly improve IOP or other endpoints of interest among patients with ...

Ginkgo Bioworks falls short on Q4 revenue and projects weak 2025 guidance. Learn about DNA stock's valuation risks, cash reserves, and financial outlook.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Cell Engineering revenue $110M-$130M with potential upside from the recent launch of Tools offerings Ginkgo expects Biosecurity ...

Ginkgo Bioworks (DNA) is down -12.5%, or -$1.29 to $9.00.Discover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving ...

Renowned for centuries, Ginkgo biloba is a well-known herbal supplement famed for its potential to bolster cognitive function, memory, and overall brain health. Sourced from the leaves of the ...

Ginkgo’s headquarters at 27 Drydock Ave. spans some 320,000 square feet, with leases that run from 2030 through 2036. The ...